Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rigetti Computing Inc (RGTI) vs TG Therapeutics Inc (TGTX) Price & Performance

Rigetti Computing IncTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Rigetti Computing Inc vs TG Therapeutics Inc — how do they compare? Rigetti Computing Inc trades at $15.33 (market cap $5.28B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.

RGTITGTX
Market Cap
$5.28B$8.53B
Sector
TechnologyHealth
52-Week High
$56.34$59.06
52-Week Low
$12.90$26.94
Enterprise Value
$4.89B$8.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rigetti Computing Inc

Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid mixed signals with bearish technical indicators but strong analyst support. The stock shows significant fundamental challenges with a P/S ratio of 391.11 and deeply negative profit margins (-1,787.4% net income margin), though recent government funding of $100 million provides crucial support. Technical analysis indicates bearish momentum with support at $15 and resistance at $17.

The outlook remains speculative with substantial execution risks and widening losses, offset by government backing and quantum computing potential. Investment opportunity hinges on long-term technology commercialization, while immediate risks include persistent cash burn and competitive pressures in the nascent quantum sector.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rigetti Computing Inc

Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.

Read more on RGTI

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX